Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, November 25, 2020
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
[ Wed, Nov 25th 2020
] - WOPRAI
David Lebovitz Maintained (ALNY) at Buy with Increased Target to $203 on, Nov 25th, 2020
David Lebovitz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Buy with Increased Target from $200 to $203 on, Nov 25th, 2020.
David has made no other calls on ALNY in the last 4 months.
There are 2 other peers that have a rating on ALNY. Out of the 2 peers that are also analyzing ALNY, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Leland Gershell of "Oppenheimer" Downgraded from Buy to Hold and Decreased Target to $156 on, Tuesday, August 11th, 2020
This is the rating of the analyst that currently disagrees with David
- Joel Beatty of "Citigroup" Initiated at Strong Buy and Held Target at $170 on, Tuesday, September 8th, 2020
